Baum Charles M's Form 4 filing
Mirati Therapeutics, Inc. (MRTX) · filed Nov 28, 2022
- Accession no.
- 0001214659-22-014229
- Filed
- Nov 28, 2022
- Trade date
- Nov 28, 2022
- Filing delay
- Same day
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 2 non-derivative transactions and 1 derivative transaction. Open-market sales total $6.93M. It was filed on the trade date.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Baum Charles MCIK 0001579824 | Director, Officer (President,Founder,Head of R&D) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Nov 28, 2022 | Common Stock | MOption exerciseAcquired | +69,256 | $17.41 | +$1,205,746.96 | 197,155 | Direct | |
| Nov 28, 2022 | Common Stock | SSaleDisposed | −69,256 | $100.00 | −$6,925,600 | 127,899 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Nov 28, 2022 | Common Stock | MOption exerciseDisposed | −69,256 | $0.00 | $0 | 69,258 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.